Publications by authors named "Susan Galbraith"

Claim this Profile
N
Neoadjuvant PARP inhibitor scheduling in BRCA1 and BRCA2 related breast cancer: PARTNER, a randomized phase II/III trial.
Jean E Abraham, Lenka Oplustil O'Connor, Louise Grybowicz, Karen Pinilla Alba, Alimu Dayimu, Susan Galbraith

Nat Commun· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Shifting the paradigm in personalized cancer care through next-generation therapeutics and computational pathology.
Jorge S Reis-Filho, Maurizio Scaltriti, Ansh Kapil, Hadassah Sade, Susan Galbraith

Mol Oncol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diversity of US participants in AstraZeneca-sponsored clinical trials.
Claudia Cabrera, Daniel Fernández-Llaneza, Zara Ghazoui, Sofia D'Abrantes, M Alejandro Esparza-Franco, Susan Galbraith

Contemp Clin Trials· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Implementation of digital health technology in clinical trials: the 6R framework.
Cristina Ortega Durán, Matthew Bonam, Elisabeth Björk, Rod Hughes, Serban Ghiorghiu, Susan Galbraith

Nat Med· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A View on Drug Development for Cancer Prevention.
Andrew R Reynolds, Michele Moschetta, Alula R Yohannes, Farzana Walcott, Marianne Ashford, Susan Galbraith

Cancer Discov· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comorbidity between lung cancer and COVID-19 pneumonia: role of immunoregulatory gene transcripts in high -expressing normal lung.
Vladimir Lazar, Jacques Raynaud, Shai Magidi, Catherine Bresson, Jean-François Martini, Susan Galbraith

Ther Adv Med Oncol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transcriptomics in Tumor and Normal Lung Tissues Identify Patients With Early-Stage Non-Small-Cell Lung Cancer With High Risk of Postsurgery Recurrence Who May Benefit From Adjuvant Therapies.
Vladimir Lazar, Nicolas Girard, Eric Raymond, Jean-François Martini, Susan Galbraith

JCO Precis Oncol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Porto European Cancer Research Summit 2021.
Ulrik Ringborg, Anton Berns, Julio E Celis, Manuel Heitor, Josep Tabernero, Susan Galbraith

Mol Oncol· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radiopotentiation Profiling of Multiple Inhibitors of the DNA Damage Response for Early Clinical Development.
Sonja J Gill, Paul W G Wijnhoven, Jacqueline H L Fok, Rebecca L Lloyd, Jonathan Cairns, Susan M Galbraith

Mol Cancer Ther· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rethinking Cancer Clinical Trial Conduct Induced by COVID-19: An Academic Center, Industry, Government, and Regulatory Agency Perspective.
Keith T Flaherty, James H Doroshow, Susan Galbraith, Antoni Ribas, Paul G Kluetz

Cancer Discov· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antibiotic use towards the end of life: development of good practice recommendations.
R Andrew Seaton, Lesley Cooper, Jack Fairweather, Stephen Fenning, Libby Ferguson, Susan Galbraith

BMJ Support Palliat Care· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Report from the SWOG Radiation Oncology Committee: Research Objectives Workshop 2017.
Paul Okunieff, Katherine Casey-Sawicki, Natalie A Lockney, Bradford S Hoppe, Heiko Enderling, Susan Galbraith

Clin Cancer Res· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer.
Vladimir Lazar, Eitan Rubin, Stephane Depil, Yudi Pawitan, Jean-François Martini, Susan Galbraith

Oncotarget· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The changing world of oncology drug development-A global pharmaceutical company's perspective.
Susan Galbraith

Chin Clin Oncol· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antibiotic treatment of urinary tract infection by community pharmacists: a cross-sectional study.
Jill L Booth, Alexander B Mullen, David A M Thomson, Christopher Johnstone, Susan J Galbraith

Br J Gen Pract· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ipilimumab increases activated T cells and enhances humoral immunity in patients with advanced melanoma.
Jeffrey S Weber, Omid Hamid, Scott D Chasalow, Dianna Y Wu, Susan M Parker, Susan Galbraith

J Immunother· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma.
David Berman, Susan M Parker, Jonathan Siegel, Scott D Chasalow, Jeffrey Weber, Susan Galbraith

Cancer Immun· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimization of donor management goals yields increased organ use.
Glen A Franklin, Ariel P Santos, Jason W Smith, Susan Galbraith, Brian G Harbrecht

Am Surg· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The antiangiogenic activity in xenograft models of brivanib, a dual inhibitor of vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinases.
Rajeev S Bhide, Louis J Lombardo, John T Hunt, Zhen-Wei Cai, Joel C Barrish, Susan Galbraith

Mol Cancer Ther· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Repeatability of 18F-FDG PET in a multicenter phase I study of patients with advanced gastrointestinal malignancies.
Linda M Velasquez, Ronald Boellaard, Georgia Kollia, Wendy Hayes, Otto S Hoekstra, Susan M Galbraith

J Nucl Med· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer.
José Baselga, Milvia Zambetti, Antoni Llombart-Cussac, Georgy Manikhas, Ernst Kubista, Susan Galbraith

J Clin Oncol· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL), a multi-targeted kinase inhibitor.
Feng Roger Luo, Yu Chen Barrett, Zheng Yang, Amy Camuso, Kelly McGlinchey, Susan Galbraith

Cancer Chemother Pharmacol· November 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metabolism and disposition of dasatinib after oral administration to humans.
Lisa J Christopher, Donghui Cui, Chiyuan Wu, Roger Luo, James A Manning, Susan Galbraith

Drug Metab Dispos· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MR in oncology drug development.
Susan M Galbraith

NMR Biomed· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18.
Natasha B Leighl, Luis Paz-Ares, Jean-Yves Douillard, Christian Peschel, Andrew Arnold, Susan Galbraith

J Clin Oncol· April 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis